Open access · CC-BY
via OpenAlex
Targeting mitophagy in Parkinson's disease
Emily H. Clark, Aurelio Vázquez de la Torre, Tamaki Hoshikawa, Thomas Briston
Journal of Biological Chemistry · 2020 · ▲ 134 citations
Mitochondrial dysfunction
Altered intercellular communication
Disabled macroautophagy
Human
Preclinical / animal
Abstract
The genetics and pathophysiology of Parkinson's disease (PD) strongly implicate mitochondria in disease aetiology. Elegant studies over the last two decades have elucidated complex molecular signaling governing the identification and removal of dysfunctional mitochondria from the cell, a process of mitochondrial quality control known as mitophagy. Mitochondrial deficits and specifically reduced mitophagy are evident in both sporadic and familial PD. Mendelian genetics attributes loss-of-function mutations in key mitophagy regulators PINK1 and Parkin to early-onset PD. Pharmacologically enhancing mitophagy and accelerating the removal of damaged mitochondria are of interest for developing a disease-modifying PD therapeutic. However, despite significant understanding of both PINK1-Parkin-dependent and -independent mitochondrial quality control pathways, the therapeutic potential of targeting mitophagy remains to be fully explored. Here, we provide a summary of the genetic evidence supporting the role for mitophagy failure as a pathogenic mechanism in PD. We assess the tractability of mitophagy pathways and prospects for drug discovery and consider intervention points for mitophagy enhancement. We explore the numerous hit molecules beginning to emerge from high-content/high-throughput screening as well as the biochemical and phenotypic assays that enabled these screens. The chemical and biological properties of these reference compounds suggest many could be used to interrogate and perturb mitochondrial biology to validate promising drug targets. Finally, we address key considerations and challenges in achieving preclinical proof-of-concept, including in vivo mitophagy reporter methodologies and disease models, as well as patient stratification and biomarker development for mitochondrial forms of the disease.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1074/jbc.rev120.014294
- Canonical
- link ↗
- Fetched
- 2026-11-12 MST
Cite this
APA
Clark, E.H., Torre, A.V.D.L., Hoshikawa, T., & Briston, T. (2020). Targeting mitophagy in Parkinson's disease. <em>Journal of Biological Chemistry</em>. https://doi.org/10.1074/jbc.rev120.014294
Vancouver
Clark EH, Torre AVDL, Hoshikawa T, Briston T. Targeting mitophagy in Parkinson's disease. Journal of Biological Chemistry. 2020. doi:10.1074/jbc.rev120.014294.
BibTeX
@article{emily2020Target,
title = {Targeting mitophagy in Parkinson's disease},
author = {Emily H. Clark and Aurelio Vázquez de la Torre and Tamaki Hoshikawa and Thomas Briston},
journal = {Journal of Biological Chemistry},
year = {2020},
doi = {10.1074/jbc.rev120.014294},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Frontiers in Aging Neuroscience 2022
Open access · CC-BY
Exploring therapeutic potential of mitophagy modulators using Drosophila models of Parkinson’s disease
The EMBO Journal 2021
Open access · CC-BY
Molecular mechanisms and physiological functions of mitophagy
Biology 2020
Open access · CC-BY
Mitophagy: A New Player in Stem Cell Biology
Cell Death and Differentiation 2012
Open access · OA
The pathways of mitophagy for quality control and clearance of mitochondria
International Journal of Molecular Sciences 2018
Open access · CC-BY
Mesenchymal Stem Cell Migration during Bone Formation and Bone Diseases Therapy
Current Biology 2018
Open access · OA